Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/23186
標題: IL-6在非小細胞肺癌之臨床意義
The clinical significance of IL-6 in non-small cell lung cancer
作者: 鍾劦媛
Chung, Shine-Yuan
關鍵字: IL-6;Interleukin-6;非小細胞肺癌;淋巴球;non-small cell lung cancer (NSCLC);tumor infiltrating lymphocytes (TIL)
出版社: 生命科學院碩士在職專班
引用: 林明泉編著。民86。臨床血清免疫學,第二版,90-106頁。藝軒出版社,台北市。 行政院衛生署臺灣地區主要死因歷年統計結果, 2004 許博欽 許世明 黃思誠 何弘能 林榮華 腫瘤免疫學:免疫監測與逃脫 台灣醫學3卷2期 250-256 (1999). Abe T, Ohno M, Sato T, Murakami M, Kajiki M, Kodaira R. "Differentiation induction" culture of human leukemic myeloid cells stimulates high production of macrophage differentiation inducing factor. Cytotechnology. 5, S75-93 (1991). Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 161, 182-7 (1999). Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, Chouaib S, Mami-Chouaib F. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer. 77, 7-12 (1998). Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 6, 583-8 (2000). Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 84, 2008-11 (1989). Begley CG. The SCL transcription factor and differential regulation of macrophage differentiation by LIF, OSM and IL-6. Stem Cells. 12, 143-51 (1994). Bhardwaj N, Santhanam U, Lau LL, Tatter SB, Ghrayeb J, Rivelis M, Steinman RM, Sehgal PB, May LT. IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources. J Immunol. 143, 2153-9 (1989). Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D''Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer. 85, 134-44 (1999). Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, Huang CY. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 289, L446-53 (2005). Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol. 23, 953-64 (2005). Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, Yen SH, Lotze MT. Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology. 60,110-5 (2001). Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today. 18, 493-7 (1997). Clogston CL, Boone TC, Crandall BC, Mendiaz EA, Lu HS. Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor. Arch Biochem Biophys. 272, 144-51 (1989). Coussens LM, Werb Z. Inflammation and cancer. Nature. 420,860-7 (2002). Cromwell O, Hamid Q, Corrigan CJ, Barkans J, Meng Q, Collins PD, Kay AB. Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1 beta and tumour necrosis factor-alpha. Immunology. 77, 330-7 (1992). Dela Cruz CS, Lee Y, Viswanathan SR, El-Guindy AS, Gerlach J, Nikiforow S, Shedd D, Gradoville L, Miller G. N-linked glycosylation is required for optimal function of Kaposi''s sarcoma herpesvirus-encoded, but not cellular, interleukin 6. J Exp Med. 199, 503-14 (2004). Devlin RB, McKinnon KP, Noah T, Becker S, Koren HS. Ozone-induced release of cytokines and fibronectin by alveolar macrophages and airway epithelial cells. Am J Physiol. 266, L612-9 (1994). De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep. 5, 649-52 (1998). Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 89, 1028-30 (2003). Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 90, 1704-6 (2004). Fraumeni JF Jr. Respiratory carcinogenesis: an epidemiologic appraisal. J Natl Cancer Inst. 55, 1039-46 (1975). Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 18, 89-95 (1997). Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol.159, 2159-65 (2001). Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege.Immunol Today. 18,240-4 (1997). Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 419, 734-8 (2002). Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb AB Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A. 86, 6367-71 (1989). Hemmann U, Gerhartz C, Heesel B, Sasse J, Kurapkat G, Grotzinger J, Wollmer A, Zhong Z, Darnell JE Jr, Graeve L, Heinrich PC, Horn F. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J Biol Chem. 271, 2999-3007 (1996). Hilton DJ, Gough NM. Leukemia inhibitory factor: a biological perspective. J Cell Biochem. 46, 21-6 (1991). Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 18, 1797-801 (1988). Hirano T, Taga T, Yasukawa K, Nakajima K, Nakano N, Takatsuki F, Shimizu M, Murashima A, Tsunasawa S, Sakiyama F, et al. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A. 84, 228-31 (1987). Hooper NM, Karran EH, Turner AJ. Membrane protein secretases. Biochem J. 321, 265-79 (1997). Hsiao YW, Liao KW, Hung SW, Chu RM. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J Immunol. 172, 1508-14 (2004). Ivan Roitt. Jonathan Brostoff. David Male.1998. Immunology, fourth edition, chapter 8-9. Mosby. England. Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A. 84, 9035-9 (1987). Janeway CA Jr. How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci U S A. 98, 7461-8 (2001). Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene. 20, 198-208 (2001). Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J.15, 43-58 (2001). Jones SA, Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex.Biochim Biophys Acta. 1592, 251-63 (2002). Joseph B, Lewensohn R, Zhivotovsky B. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann N Y Acad Sci. 26, 204-16 (2000). Jourdan M, Bataille R, Seguin J, Zhang XG, Chaptal PA, Klein B. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum. 33, 398-402 (1990). Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, Vignaud JM. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med. 140, 320-8 (2002). Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 332, 83-5 (1988). Lee JD, Sievers TM, Skotzko M, Chandler CF, Morton DL, McBride WH, Economou JS. Interleukin-6 production by human melanoma cell lines. Lymphokine Cytokine Res. 11,161-6 (1992). Leng SX, Elias JA. Interleukin-11. Int J Biochem Cell Biol. 29, 1059-62 (1997). Luger TA, Krutmann J, Kirnbauer R, Urbanski A, Schwarz T, Klappacher G, Kock A, Micksche M, Malejczyk J, Schauer E, et al. IFN-beta 2/IL-6 augments the activity of human natural killer cells.J Immunol. 143, 1206-9 (1989). Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T, et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 263, 89-92 (1994). Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, Brito MJ, Oramas J. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine. 11, 80-6 (1999). Marz P, Otten U, Rose-John S. Neural activities of IL-6-type cytokines often depend don soluble cytokine receptors. Eur J Neurosci. 11, 2995-300 (1999). May LT, Sehgal PB. Phosphorylation of interleukin-6 at serine54: an early event in the secretory pathway in human fibroblasts. Biochem Biophys Res Commun. 185, 524-30 (1992). McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 91, 1993-5 (2004). Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, Tsuji S, Kawaguchi M, Nakajima S, Kobayashi H, Masui T, Imamura M. Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer Res. 21, 2449-56 (2001). Musashi M, Yang YC, Paul SR, Clark SC, Sudo T, Ogawa M. Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci U S A. 88, 765-9 (1991). Nawata Y, Eugui EM, Lee SW, Allison AC. IL-6 is the principal factor produced by synovia of patients with rheumatoid arthritis that induces B-lymphocytes to secrete immunoglobulins. Ann N Y Acad Sci. 557,230-8 (1989). Orita T, Oheda M, Hasegawa M, Kuboniwa H, Esaki K, Ochi N. Polypeptide and carbohydrate structure of recombinant human interleukin-6 produced in Chinese hamster ovary cells. J Biochem (Tokyo). 115, 345-50 (1994). Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP. Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer. 36, 17-25 (2002). Pennica D, Shaw KJ, Swanson TA, Moore MW, Shelton DL, Zioncheck KA, Rosenthal A, Taga T, Paoni NF, Wood WI. Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J Biol Chem. 270, 10915-22 (1995). Petty LT. Lung cancer. Postgard Med. 101, 121-2 (1997). Poupart P, Vandenabeele P, Cayphas S, Van Snick J, Haegeman G, Kruys V, Fiers W, Content J. B cell growth modulating and differentiating activity of recombinant human 26-kd protein (BSF-2, HuIFN-beta 2, HPGF). EMBO J. 6, 1219-24 (1987). Revel M, Zilberstein A. Interferon-beta 2 living up to its name. Nature. 325, 581-2 (1987). Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 300, 281-90 (1994). Saji H, Nakamura H, Awut I, Kawasaki N, Hagiwara M, Ogata A, Hosaka M, Saijo T, Kato Y, Kato H. Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. Ann Thorac Cardiovasc Surg. 9, 295-300 (2003). Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 87, 264-7 (2002). Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, Huber C. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res.56, 1756-60 (1996). Shalaby MR, Waage A, Espevik T. Cytokine regulation of interleukin 6 production by human endothelial cells. Cell Immunol. 121, 372-82 (1989). Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 61, 237-42 (2001). Sirzen F, Zhivotovsky B, Nilsson A, Bergh J, Lewensohn R. pontaneous and radiation-induced apoptosis in lung carcinoma cells with different intrinsic radiosensitivities. Anticancer Res. 18, 695-9 (1998). Tajima S, Tsuji K, Ebihara Y, Sui X, Tanaka R, Muraoka K, Yoshida M, Yamada K, Yasukawa K, Taga T, Kishimoto T, Nakahata T. Analysis of interleukin 6 receptor and gp130 expressions and proliferative capability of human CD34+ cells. J Exp Med. 184, 1357-64 (1996). Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 90, 11924-8 (1993). To Y, Dohi M, Matsumoto K, Tanaka R, Sato A, Nakagome K, Nakamura T, Yamamoto K. A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line. Am J Respir Cell Mol Biol. 27, 220-6 (2002). Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 259, 368-70 (1993). Walker PR, Saas P, Dietrich PY. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol. 10, 564-72 (1998). Wang LS, Chow KC, Wu CW. Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer. 80, 1617-22 (1999). Wang LS, Chow KC, Li WY, Liu CC, Wu YC, Huang MH. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma. Clin Cancer Res. 6, 1445-51 (2000). Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, Motohashi S, Yokoi S, Hiroshima K, Tagawa M, Nakayama T, Fujisawa T. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother. 53, 786-92 (2004). Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 71, 1095-8 (1995). Yasukawa K, Hirano T, Watanabe Y, Muratani K, Matsuda T, Nakai S, Kishimoto T. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J. 6, 2939-45 (1987). Yoshida Y, Maruyama M, Fujita T, Arai N, Hayashi R, Araya J, Matsui S, Yamashita N, Sugiyama E, Kobayashi M. Reactive oxygen intermediates stimulate interleukin-6 production in human bronchial epithelial cells. Am J Physiol.276, L900-8 (1999). http://nic.sav.sk/logos/books/scientific/node32.htm
摘要: 
IL-6,具有多樣性生物功能的細胞激素,對於免疫反應調控、急性發炎反應甚至與腫瘤生成均有關。在許多腫瘤如前列腺癌、乳癌、大腸癌、卵巢癌、肺癌,病患血清若表現高濃度IL-6預後會較差;對於荷爾蒙治療、放射線治療、化學治療效果均不好。在本篇論文,利用反轉錄聚合酶連鎖反應(RT-PCR)、原位雜交反應(ISH)與組織免疫染色(IHC)方法分析59位經病理診斷為非小細胞肺癌病患的肺部及淋巴結檢體,分析IL-6 mRNA及蛋白質在非小細胞肺癌的來源與位置。同時比較非小細胞肺癌表現IL-6 mRNA預後情況。在原位雜交的結果,NSCLC腫瘤部位IL-6 mRNA陽性表現為27.11%;在非腫瘤部位中,IL-6 mRNA陽性表現為50.84%。以半定量RT-PCR測得的結果,也同樣顯示在非腫瘤部位IL-6 mRNA高於腫瘤部位。比較NSCLC存活率與IL-6表現的關係,表現IL-6 mRNA患者(n=16)預後存活高於不表現IL-6 mRNA的患者(n=43)(p=0.015)。表示非小細胞肺癌患者,腫瘤細胞表現IL-6 mRNA預後較好。利用組織免疫染色來觀察非小細胞肺癌檢體中IL-6蛋白分佈的情形,腫瘤部位表現IL-6陽性為18.64%;非腫瘤部位中,IL-6陽性表現為64.4%。表示IL-6 mRNA、蛋白質大多表現在非腫瘤細胞。以淋巴球及巨噬細胞為主。因此同時使用巨噬細胞標記抗體(CD68),藉以分辨巨噬細胞與淋巴球細胞何者表現IL-6 mRNA。結果在非腫瘤細胞中IL-6 mRNA與蛋白質表現以淋巴球為主。綜合比較ISH及IHC結果得知,在NSCLC非腫瘤部位,所測得IL-6 mRNA與IL-6蛋白質表現強度均高於腫瘤部位。在非腫瘤細胞中IL-6 mRNA與蛋白質表現以淋巴球為主。非小細胞肺癌患者,表現IL-6 mRNA者預後較好。

Interleukin-6 (IL-6) plays an important role in the proliferation of cancer cells and correlates with disease progression and prognosis. In this study we identified the source and the clinical roles of IL-6 in non-small cell lung cancer (NSCLC).Tissue specimens were collected from 59 patients undergone surgery for NSCLC. Detection of IL-6 mRNA was determined by in situ hybridization (ISH) and reverse transcription polymerase chain reaction (RT-PCR). Expression of IL-6 protein was identified by immunohistochemical staining (IHC). IL-6 mRNA was identified by ISH in non-tumor parts (n=43; 50.84%) and tumor parts (n=16; 27.11%) and expression IL-6 mRNA was correlated with patients,survival. Semi-quantitative RT-PCR confirmed IL-6 mRNA was mainly produced by non-tumor cells. IL-6 protein was identified in non-tumor parts (n=38; 64.4%) and tumor parts (n=11;18.64%). Tumor associated macrophages (TAM) and tumor infiltrating lymphocytes (TIL) were two major source producing IL-6. We further used CD68 antibody in immune staining to differential TAM and TIL at the same time. We confirmed that tumor infiltrating lymphocytes were the major sources of IL-6 in NSCLC. These results show that IL-6 in NSCLC, non-tumor parts express higher IL-6 mRNA and protein than tumor parts, especially tumor infiltrating lymphocytes. Patients with NSCLC, expressing high levels IL-6 mRNA associated with good prognosis.
URI: http://hdl.handle.net/11455/23186
其他識別: U0005-0308200610444000
Appears in Collections:生命科學系所

Show full item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.